Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
ICON 9 will assess the efficacy, safety and tolerability of maintenance olaparib in
combination with cediranib compared to maintenance olaparib alone following a response to
platinum-based chemotherapy in women with relapsed platinum-sensitive ovarian, fallopian tube
or peritoneal cancer. Prognostic and predictive factors will be studied from tumour and blood
samples.